Teva Pharmaceutical Industries (TEVA) said Tuesday that it has exercised its right to further raise the pool tender cap for its pool 3 notes to a total purchase price of $400 million from $350 million previously.
The pool 3 notes consist of US dollar-denominated 7.875% sustainability-linked senior notes due 2029, Euro-denominated 7.375% sustainability-linked senior notes due 2029, and US dollar-denominated 8.125% sustainability-linked senior notes due 2031, the company added.
Teva said the pool tender caps for the pool 1 notes, which consist of US dollar-denominated 3.150% senior notes due 2026, and the pool 2 notes, which consist of US dollar-denominated 4.750% sustainability-linked senior notes due 2027 and Euro-denominated 3.750% sustainability-linked senior notes due 2027, remain unchanged.
The combined total purchase price of the notes is increased to $2.30 billion from $2.25 billion, Teva said.
A total of $2.60 billion of the pool 1 notes have been tendered, while a total of $1.39 billion of the pool 2 notes and $717.6 million of the pool 3 notes have been tendered so far as part of early tender offer results, Teva said, adding that the tender offers will expire on June 17.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。